Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
High-Dose Cytarabine and Mitoxantrone in Treating Patients With Juvenile Myelomonocytic Leukemia Undergoing a Second Donor Stem Cell Transplant
This study is currently recruiting participants.
Study NCT00609739 Information provided by National Cancer Institute (NCI)
First Received: February 6, 2008 Last Updated: April 2, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cyclosporine
cytarabine
isotretinoin
methotrexate
methylprednisolone
mitoxantrone hydrochloride
Additional drug interventions recognized in this trial
Cyclosporins
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mitoxantrone
Prednisolone
Prednisolone acetate
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Analgesics
Anti-Infective Agents
Anti-Inflammatory Agents
Antiemetics
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Antiviral Agents
Autonomic Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Nucleic Acid Synthesis Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reproductive Control Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Back to top of Main Content
